TCD IS AN AFRICAN-FOCUSED CRO
WITH A FULL-SERVICE OFFERING
Triclinium Clinical Development (TCD) is a Contract Research Organisation (CRO) headquartered in Centurion (Pretoria), South Africa. Since its inception in February 2000, TCD has been awarded over 300 clinical trial contracts, across 16 therapeutic areas, by more than 120, predominantly international, clients. These contracts included single stand-alone audits to full-service contracts and spanned all phases of clinical research from single-dose First-in-Human Phase I trials to large multicentre Phase III, and Phase IV trials. In November 2016, TCD was acquired by EOH Abantu, a wholly-owned subsidiary of EOH Holdings, a listed entity on the Johannesburg Stock Exchange (JSE).
Cost-effective risk reduction and quality maintenance in our clients’ projects. Providing input into development and GTM strategies, facilitating fund-raising, participating in co-development and risk sharing.
We partner with centres of excellence to drive efficient early development, getting our clients to GO/NOGO decisions faster through effective design and conduct of First-In-Human, BA/BE, Biosimilar and other early-phase studies. We have a strong network of pre-clinical services with strategic partners across the globe.
PHASE II & III
Partnering with our customers to bring products to market efficiently and effectively, saving time, reducing costs and improving quality using innovative and adaptive digital technology in clinical trials.